TABLE 2.

Analysis of distinct epitope binding of MAbs by competition ELISA

MAbEpitope groupa% Inhibition of the following HRP-labeled MAbb:
MA7EA4EA5EA8MA4EA6EA2EA3MA1EA1Con1Con2EA7MA2MA3MA5MA6EB-A2c
MA7I8681758145123000308000000
EA4I82907885570134136725001020
EA5I8385827745054006542700070
EA8I76846878380711005402100000
MA4I7891698870091002831800020
EA6I8492858750062006002800000
EA2II00000096758888000001200
EA3II000000957577821710001300
MA1II0000006708100000900
EA1II0000008810753600000900
Con1III65120040200093471500000
Con2III200000000093181600000
EA7IV000000020000000000
MA2V0070100000002902000
MA3VI0000005700000000100
MA5VII0017040000000000000
MA6VIII006000000000000000
  • a The competition ELISA was performed to analyze the binding epitopes of the different MAbs. By use of the criteria described in Materials and Methods, 17 MAbs were divided into eight groups, with each group reacting with the same epitope or sterically overlapping epitopes on Aspergillus antigens. The experiment was repeated with similar results.

  • b Competitive inhibition values ≥75% are in boldface.

  • c EB-A2, a rat anti-GM MAb supplied with the commercial Platelia Aspergillus kit.